dc.contributor.author | Bokil, Ansooya Avinash | |
dc.contributor.author | Børkja, Mathieu | |
dc.contributor.author | Wolowczyk, Camilla Izabel | |
dc.contributor.author | Lamsal, Apsana | |
dc.contributor.author | Prestvik, Wenche S. | |
dc.contributor.author | Nonstad, Unni | |
dc.contributor.author | Pettersen, Kristine | |
dc.contributor.author | Andersen, Sonja Benedikte | |
dc.contributor.author | Bofin, Anna M. | |
dc.contributor.author | Bjørkøy, Geir | |
dc.contributor.author | Hak, Sjoerd | |
dc.contributor.author | Giambelluca, Miriam Soledad | |
dc.date.accessioned | 2023-12-13T10:08:17Z | |
dc.date.available | 2023-12-13T10:08:17Z | |
dc.date.issued | 2023-11-18 | |
dc.description.abstract | Background: Myeloid cells play an essential role in cancer metastasis. The phenotypic diversity of these cells during cancer development has attracted great interest; however, their functional heterogeneity and plasticity have limited their role as prognostic markers and therapeutic targets. <p><p>Methods: To identify markers associated with myeloid cells in metastatic tumours, we compared transcriptomic data from immune cells sorted from metastatic and non-metastatic mammary tumours grown in BALB/cJ mice. To assess the translational relevance of our in vivo findings, we assessed human breast cancer biopsies and evaluated the association between arginase 1 protein expression in breast cancer tissues with tumour characteristics and patient outcomes. <p>Results: Among the differentially expressed genes, arginase 1 (ARG1) showed a unique expression pattern in tumour-infiltrating myeloid cells that correlated with the metastatic capacity of the tumour. Even though ARG1-positive cells were found almost exclusively inside the metastatic tumour, ARG1 protein was also present in the plasma. In human breast cancer biopsies, the presence of ARG1-positive cells was strongly correlated with high-grade proliferating tumours, poor prognosis, and low survival. <p>Conclusion: Our findings highlight the potential use of ARG1-positive myeloid cells as an independent prognostic marker to evaluate the risk of metastasis in breast cancer patients. | en_US |
dc.identifier.citation | Bokil AA, Børkja MB, Wolowczyk CI, Lamsal A, Prestvik WS, Nonstad U, Pettersen K, Andersen SB, Bofin A M, Bjørkøy GB, Hak S, Giambelluca M. Discovery of a new marker to identify myeloid cells associated with metastatic breast tumours. Cancer Cell International. 2023;23 | en_US |
dc.identifier.cristinID | FRIDAID 2198711 | |
dc.identifier.doi | 10.1186/s12935-023-03136-w | |
dc.identifier.issn | 1475-2867 | |
dc.identifier.uri | https://hdl.handle.net/10037/32048 | |
dc.language.iso | eng | en_US |
dc.publisher | BMC | en_US |
dc.relation.journal | Cancer Cell International | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.title | Discovery of a new marker to identify myeloid cells associated with metastatic breast tumours | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |